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of human CD8+ T cell lines specific to islet-associated autoantigens 
 
Jenny Aurielle B. Babon, David M. Harlan and Sally C. Kent   
 
Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, MA  
 
Abstract: 
Type 1 diabetes (T1D) is an autoimmune disease characterized by the activation of 
lymphocytes against insulin-producing β-cells in the pancreas. In humans, CD8+ T cells are 
predominantly found in sites of insulitis and are considered to be one of the main drivers of β-
cell destruction, thus indicating the need to analyze the frequency and function of these 
autoreactive CD8+ T cells. Peripheral blood mononuclear cells (PBMC) from individuals with 
long-term T1D were stained ex vivo for T cell surface markers and HLA-A2 pentamers 
containing known islet-associated epitopes to determine if there are autoreactive CD8+ T cells 
circulating in the periphery. All T1D donors tested had at least one detectable autoreactive CD8 
T cell population and the frequencies of these autoantigen-specific T cells were comparable to 
previously published data from T1D individuals. We then developed a method of establishing 
CD8 T cell lines by co-culturing negatively isolated CD8 T cells and peptide-pulsed monocyte-
derived dendritic cells from the PBMC of one T1D donor (A*02:01, A*33:01, B*14:02, B*40:01, 
DRB1*01:02, DRB1*04:04). We expanded a CD8 T cell line specific to the preproinsulin peptide 
PPI15-24. This cell line produced IFN-γ and expressed CD107a in the presence of PPI15-24-pulsed 
target cells, but not to an unrelated peptide or media alone. Using a similar approach, we were 
able to generate CD8 T cell lines from the same T1D donor that were cytotoxic to target cells 
pulsed with the autoantigens glutamic acid decarboxylase peptide (GAD65114-123) and islet-
specific glucose-6-phosphatase catalytic subunit-related protein peptide (IGRP265-273). These 
autoreactive T cell lines can be utilized in in vivo assays using humanized mouse models to 
further understand the mechanism of β-cell destruction and disease progression. Studying the 
functionalities of these autoreactive T cells will also provide insights into identifying immune 
correlates to better assess both novel and existing immunotherapeutic strategies for T1D. 
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